New collaboration between Neuraxpharm and Bened Biomedical expands portfolio of Consumer Healthcare products Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) … Continue reading “Neuraxpharm launches first probiotic product PS128™”
22.MAY 2019 AT 18:00:00 CET Collaboration will support Phase III clinical trial of cell therapy product ATIR101(TM) for blood cancers MINNEAPOLIS & AMSTERDAM, May 22, 2019 – Be The Match BioTherapies®, an … Continue reading “Be The Match BioTherapies® and Kiadis Pharma Announce Strategic Collaboration To Accelerate Patient Access To Haploidentical Stem Cell Therapies”
Amsterdam, The Netherlands, May 22, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announced that it has submitted … Continue reading “Kiadis Submits Response to the European Medicines Agency’s Day 180 Second List of Outstanding Issues”
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces its unaudited interim results for the six months ended 31 March 2019. Highlights Commercial and Operational … Continue reading “IXICO plc – Half Yearly Report to 31 March 2019”
TURKU, Finland, May 21, 2019 /PRNewswire/ — DelSiTech Ltd, a Finnish drug delivery and drug development company, today announced significant grant funding to support the development of long-acting controlled release formulations for family … Continue reading “DelSiTech Ltd Receives Significant Funding from the Bill & Melinda Gates Foundation for Developing Long-Acting Injectables”
Secure supply and first vial presentation of a pivotal drug for acute promyelocytic leukaemia FARNBOROUGH, England, May 20, 2019: Flexipharm Austrading the UK specialty pharmaceutical company focused on supplying the NHS with … Continue reading “Flexipharm Austrading announces launch of Arsenic Trioxide Phebra (arsenic trioxide 1mg/ml concentrate for solution for infusion)”
Dr Mark Albertella appointed VP Translational Oncology 20 May 2019, Cambridge, UK: STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, today announced that it … Continue reading “STORM Therapeutics extends Series A to GBP 30M (USD 38.43M) with new investor, Seroba Life Sciences”
Seasoned pharma & biotech executive joins the Board of mid-stage clinical company Lausanne, SWITZERLAND and Cambridge, MA, USA, May 20, 2019 – Asceneuron, an emerging leader in the development of … Continue reading “Asceneuron appoints experienced CNS clinician Dr Eric Yuen to the Board of Directors”
LOS ANGELES, CA, May 16, 2019 – ImaginAb Inc., a clinical stage immuno-oncology imaging company, announces it has enrolled its first patient for the Phase II clinical trial of its lead … Continue reading “ImaginAb Enrolls First Patient in Phase II Clinical Trial at a World-Leading Cancer Center in Los Angeles County”
Awarded €2M grant and completes seed financing to develop high-precision point-of-care Hemophilia Biochip device April 30th, 2019 Nijmegen, Netherlands: Enzyre, which is developing breakthrough ambulant diagnostic technology for coagulation testing, … Continue reading “Enzyre appoints Dirk Pollet as Chief Executive Officer”
On track to deliver robust revenue growth from £21.2m order book Strong closing cash balance of £7.5m as at 31 March 2019 IXICO plc (AIM: IXI), the data analytics company … Continue reading “IXICO plc Trading update for the first half of financial year ending 31 March 2019”
Providing specialist imaging clinical trials services for rare neurological diseases IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces that it has signed contracts with … Continue reading “IXICO announces two new biopharmaceutical contracts”
LOS ANGELES, 17 April 2019 – ImaginAb Inc., a clinical stage immuno-oncology imaging company, today announces that it is scheduled to present at the following investor and scientific conferences in April … Continue reading “ImaginAb to Present at Upcoming Investor and Scientific Conferences in April and May 2019”
Transaction creates leader in cell-based cancer immunotherapy, with complementary T-cell and NK-cell platforms focused initially on hematopoietic stem cell transplants (HSCT) CytoSen’s lead NK-cell therapy candidate, CSDT002-NK, is expected to … Continue reading “Kiadis to Acquire CytoSen Therapeutics, Inc.”
Sustained Progress made in 2018 Futura Medical plc (AIM: FUM), the pharmaceutical company developing a portfolio of innovative products for sexual health and pain, based on its proprietary, transdermal DermaSys® … Continue reading “Futura Medical Preliminary Results for the year ended 31 December 2018”
LOS ANGELES, 4 April 2019 – ImaginAb Inc., a clinical stage immuno-oncology imaging company, congratulates Dr. Antoni Ribas, Ph.D., member of its Science Advisory Board, on his selection as President-Elect … Continue reading “AACR Elects ImaginAb Science Advisory Board Member, Dr. Antoni Ribas, as President-Elect at 2019 Annual Meeting”
F2G appoints Dr Patrick Vink as Chairman Brings successful track record of building and growing global businesses MANCHESTER, UK & VIENNA, AUSTRIA – 8 April 2019 – F2G Ltd, the European … Continue reading “F2G appoints Dr Patrick Vink as Chairman”
Apr 5, 2019 Stockholm, Sweden, April 5, 2019 – The nomination committee of Calliditas Therapeutics AB (NASDAQ Stockholm: CALTX) (“Calliditas”) has proposed that Elmar Schnee and Diane Parks be elected … Continue reading “Elmar Schnee and Diane Parks proposed as new board members of Calliditas Therapeutics”
Attendance at key European psychiatry summit underlines commitment to medical community CEO Dr. Jörg-Thomas Dierks to attend psychiatry Congress being held in Warsaw April 5, 2019 Neuraxpharm Group, a leading … Continue reading “Neuraxpharm attends 27th European Congress of Psychiatry”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2019 Optimum Strategic Communications All rights reserved.
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com